ACTengine® IMA203 Combined With mRNA-4203
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorImmatics US, Inc.
About this trial
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Eligibility criteria
Qualifiers
Pathologically confirmed and documented cutaneous melanoma (CM) or synovial sarcoma (SS) with unresectable or metastatic disease
HLA-A*02:01 positive
Adequate selected organ function per protocol
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Disqualifiers
History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
Pregnant or breastfeeding
Serious autoimmune disease
History of cardiac conditions as per protocol
Trial design
Treatments tested in this trial
- IMA203
- mRNA-4203
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Immatics US, Inc.
Lead sponsor
ModernaTX, Inc.
Collaborator
Source ClinicalTrials.gov